Brain Advance Access published online on July 14, 2006
Brain, doi:10.1093/brain/awl162
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Center for Neurosciences, Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System, Manhasset, NY, USA; Department of Neurology, North Shore University Hospital and New York University School of Medicine, NY, USA
* To whom correspondence should be addressed. It has been proposed that deep brain stimulation (DBS) of the subthalamic nucleus (STN DBS) and dopaminergic therapy ameliorate the symptoms of Parkinson's disease through similar functional mechanisms. We examined this notion using PET to compare the metabolic effects of these treatment approaches. Nine Parkinson's disease patients (age 61.7 ± 11.1 years) were scanned ON and OFF STN stimulation and nine others (age 60.0 ± 9.3 years) were scanned ON and OFF an individual titrated intravenous levodopa infusion. The two treatment groups were matched for baseline disease severity as well as clinical response to therapy. Similarities and differences in the effects of treatment on regional metabolism were assessed using statistical parametric mapping (SPM). In addition, we used network analysis to assess the effect of therapy on the expression of an abnormal Parkinson's disease-related spatial covariance pattern (PDRP). We found that both STN DBS and levodopa therapy were associated with significant (P < 0.001) metabolic reductions in the putamen/globus pallidus, sensorimotor cortex and cerebellar vermis, as well as increases in the precuneus (BA 7). The metabolic effects of the two interventions differed in the STN and medial prefrontal cortex, with relative increases with stimulation in the former structure and decreases in the latter. Network quantification disclosed reductions in PDRP activity with both interventions, which correlated with clinical improvement (P < 0.05). The degree of network modulation by therapy did not differ significantly for the two treatment approaches (P > 0.6). These findings support the results of previous imaging studies indicating that effective symptomatic therapies for Parkinson's disease involve a common mechanism. The modulation of pathological brain networks is a critical feature of the treatment response in parkinsonism.
Received March 17, 2006
Revised May 16, 2006
Accepted May 20, 2006
Article
Network modulation in the treatment of Parkinson's disease
Kotaro Asanuma 1,
Chengke Tang 1,
Yilong Ma 1,
Vijay Dhawan 1,
Paul Mattis 1,
Christine Edwards 1,
Michael G. Kaplitt 2,
Andrew Feigin 1,
and
David Eidelberg 1 *
2 Department of Neurosurgery, Weil-Cornell Medical Center, NY, USA
David Eidelberg, E-mail: david1{at}nshs.edu
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. B. Montgomery Jr and R. Hilker STN-DBS ACTIVATES THE TARGET AREA IN PARKINSON DISEASE Neurology, July 28, 2009; 73(4): 327 - 328. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kelly, G. de Zubicaray, A. Di Martino, D. A. Copland, P. T. Reiss, D. F. Klein, F. X. Castellanos, M. P. Milham, and K. McMahon L-Dopa Modulates Functional Connectivity in Striatal Cognitive and Motor Networks: A Double-Blind Placebo-Controlled Study J. Neurosci., June 3, 2009; 29(22): 7364 - 7378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Narayana, A. Jacks, D. A. Robin, H. Poizner, W. Zhang, C. Franklin, M. Liotti, D. Vogel, and P. T. Fox A Noninvasive Imaging Approach to Understanding Speech Changes Following Deep Brain Stimulation in Parkinson's Disease Am J Speech Lang Pathol, May 1, 2009; 18(2): 146 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Argyelan, M. Carbon, M.-F. Ghilardi, A. Feigin, P. Mattis, C. Tang, V. Dhawan, and D. Eidelberg Dopaminergic Suppression of Brain Deactivation Responses during Sequence Learning J. Neurosci., October 15, 2008; 28(42): 10687 - 10695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Karimi, N. Golchin, S. D. Tabbal, T. Hershey, T. O. Videen, J. Wu, J. W. M. Usche, F. J. Revilla, J. M. Hartlein, A. R. Wernle, et al. Subthalamic nucleus stimulation-induced regional blood flow responses correlate with improvement of motor signs in Parkinson disease Brain, October 1, 2008; 131(10): 2710 - 2719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Wu and M Hallett Neural correlates of dual task performance in patients with Parkinson's disease J. Neurol. Neurosurg. Psychiatry, July 1, 2008; 79(7): 760 - 766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. P. Lin, M. Carbon, C. Tang, A. Y. Mogilner, D. Sterio, A. Beric, V. Dhawan, and D. Eidelberg Metabolic correlates of subthalamic nucleus activity in Parkinson's disease Brain, May 1, 2008; 131(5): 1373 - 1380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hirano, K. Asanuma, Y. Ma, C. Tang, A. Feigin, V. Dhawan, M. Carbon, and D. Eidelberg Dissociation of Metabolic and Neurovascular Responses to Levodopa in the Treatment of Parkinson's Disease J. Neurosci., April 16, 2008; 28(16): 4201 - 4209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Nandhagopal, M. J. McKeown, and A. J. Stoessl Invited Article: Functional imaging in Parkinson disease Neurology, April 15, 2008; 70(16_Part_2): 1478 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Feigin, M. G. Kaplitt, C. Tang, T. Lin, P. Mattis, V. Dhawan, M. J. During, and D. Eidelberg Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease PNAS, December 4, 2007; 104(49): 19559 - 19564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Huang, C. Tang, A. Feigin, M. Lesser, Y. Ma, M. Pourfar, V. Dhawan, and D. Eidelberg Changes in network activity with the progression of Parkinson's disease Brain, July 1, 2007; 130(7): 1834 - 1846. [Abstract] [Full Text] [PDF]
|
|